



# Galleri® multi-cancer early detection test

## Feedback on its value as a Medicare Advantage Benefit

The following excerpts are from market research which surveyed **1,000 US participants**. The goal was to understand their relative preference of the Galleri multi-cancer early detection test compared to other Medicare Advantage plan supplemental benefits.



### Next-level cancer screening designed to detect the previously undetectable.<sup>1</sup>


Galleri screens for more than 50+ types cancers via a shared cancer signal and predicts its origin with high accuracy<sup>2\*</sup>

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

## After vision and dental, Galleri® would be the most important supplemental benefit for current and age-in MA beneficiaries

### Relative Importance of Supplemental Benefits

Maxdiff score



Base: All respondents (N=1000)  
Q250. Looking at the following supplemental benefits which could be offered by your Medicare (IF MA\_BENEFICIARIES: Advantage) plan, please select the one benefit that would be most important to you, and the one benefit that would be least important to you. See notes for benefit definitions shown to respondents.

## Medicare Care Advantage members describe Galleri as more innovative than other potential supplemental benefits.

**71%** have positive impression of Galleri  
% respondents selecting

**73%** describe Galleri as extremely or very innovative (ahead of all other potential supplemental benefits)  
% respondents selecting

Market Research Data on file GA-2023-0101

\*In the PATHFINDER study, Cancer Signal Origin (CSO) prediction accuracy was 88% for participants with a cancer diagnosis among study participants with "Cancer Signal Detected" test result.

# What they said about a Multi-Cancer Early Detection Test

## Respondent verbatims



It would just mean so much to have a test that could give a better idea of where my body stands as far as different cancers.



I think this screening would be very helpful.



It's an interesting concept and I would likely take advantage of it.



This sounds promising, and could be a game changer.

Market Research Data on file GA-2023-0101

The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

## Galleri® supports enrollment and member satisfaction

# 65%

would be more satisfied with a Medicare health insurance that offered Galleri

\*respondents choosing strongly or somewhat agree

# 60%

of members would be more likely to re-enroll in their MA plan with Galleri as a benefit.

\*respondents choosing strongly or somewhat agree

Market Research Data on file GA-2023-0101



## Galleri is the first-of-its-kind blood test for multi-cancer early detection.



Learn more  
Galleri.com



### Contact Us

National Accounts and Galleri® Medicare Advantage Research: [payers@grailbio.com](mailto:payers@grailbio.com)

### Important Safety Information:

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of "No Cancer Signal Detected" does not rule out cancer. A test result of "Cancer Signal Detected" requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. **Rx only.**

### Laboratory / Test Information:

GRAIL's clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL's clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

- Schrag D, et al. PATHFINDER: A Prospective Study of a Multi-Cancer Early Detection Blood Test. Presentation at European Society of Medical Oncology (ESMO) Congress September 9-13, 2022; Paris, France.
- Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. *Ann Oncol.* 2021;32(9):1167-1177. Doi: 10.1016/j.annonc.2021.05.806.